MedPath

Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida

A note on fungal infection prophylaxis

Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.

A note on laboratory testing

Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome

Not Applicable
Completed
Conditions
Meningitis, Cryptococcal
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Pfizer
Registration Number
NCT00002074
Locations
🇺🇸

Dr Richard Meyer, Los Angeles, California, United States

🇺🇸

DeKalb Gen Hosp, Decatur, Georgia, United States

🇺🇸

Shallowford Hosp, Decatur, Georgia, United States

and more 36 locations

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

Phase 3
Completed
Conditions
Mycoses
Mycobacterium Avium-Intracellulare Infection
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Pfizer
Target Recruit Count
720
Registration Number
NCT00002122
Locations
🇺🇸

Los Angeles County - USC Med Ctr, Los Angeles, California, United States

🇺🇸

UCSD Treatment Ctr / Dept of Medicine and Pediatrics, San Diego, California, United States

🇺🇸

Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States

and more 9 locations

Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

Not Applicable
Completed
Conditions
Meningitis, Cryptococcal
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Pfizer
Registration Number
NCT00002076
Locations
🇺🇸

Summitt Med Ctr / San Francisco Gen Hosp, Oakland, California, United States

🇺🇸

Cornell Univ Med Ctr, New York, New York, United States

🇺🇸

Buckley Braffman Stern Med Associates, Philadelphia, Pennsylvania, United States

A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Not Applicable
Completed
Conditions
Meningitis, Cryptococcal
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Pfizer
Registration Number
NCT00002068
Locations
🇺🇸

Christiana Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States

🇺🇸

Univ of Tennessee, Memphis, Tennessee, United States

🇺🇸

Davies Med Ctr, San Francisco, California, United States

and more 5 locations

Dexamethasone in Cryptococcal Meningitis

Phase 2
Completed
Conditions
Meningitis, Cryptococcal
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
36
Registration Number
NCT00000776
Locations
🇺🇸

Northwestern Univ Med School, Chicago, Illinois, United States

🇺🇸

Cook County Hosp, Chicago, Illinois, United States

🇺🇸

Univ of Miami School of Medicine, Miami, Florida, United States

and more 11 locations

Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

Not Applicable
Completed
Conditions
Meningitis, Cryptococcal
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Pfizer
Registration Number
NCT00002040
Locations
🇺🇸

Cook County Hosp, Chicago, Illinois, United States

🇺🇸

Summitt Med Ctr / San Francisco Gen Hosp, Oakland, California, United States

🇺🇸

Cornell Univ Med Ctr, New York, New York, United States

and more 2 locations

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

Phase 2
Completed
Conditions
Meningitis, Cryptococcal
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2009-06-03
Lead Sponsor
InterMune
Target Recruit Count
60
Registration Number
NCT00012467
Locations
🇺🇸

Houston Veterans Administration Med Ctr, Houston, Texas, United States

🇺🇸

Univ of Texas / Med School at Houston, Houston, Texas, United States

🇵🇪

Instituto de Medicina Tropical, Lima, Peru

and more 6 locations

Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis

Phase 2
Completed
Conditions
Histoplasmosis
Sporotrichosis
Blastomycosis
First Posted Date
2000-02-25
Last Posted Date
2006-06-09
Lead Sponsor
National Center for Research Resources (NCRR)
Target Recruit Count
78
Registration Number
NCT00004808

Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis

Phase 2
Completed
Conditions
Sporotrichosis
First Posted Date
2000-02-25
Last Posted Date
2006-06-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
30
Registration Number
NCT00004938
© Copyright 2025. All Rights Reserved by MedPath